MACH7 TECHNOLOGIES LIMITED — Capital/Financing Update 2016

May 5, 2016

ASX Announcement

6 May 2016

==> picture [610 x 89] intentionally omitted <==

Mach7 Completes Enterprise Imaging Platform Implementation at Premier US Radiology Group

• Software implementation complete at five sites following successful pilot program

• Software currently being rolled out across remaining 20 sites

• Subscription revenues expected up to A$650k p.a.

• Current RFPs with 6 hospital groups offer combined contract value of >A$8m

Melbourne, Australia; 6 May 2016: Mach7 Technologies Limited ( Mach7 ) (ASX: M7T ) today announced that it has successfully completed a pilot program with a leading U.S. radiology group of Mach7 Enterprise Imaging Platform and is commencing roll-out to all remaining sites within the group.

Completion of the pilot program involved Mach7 working with its integration partners on the multi-site installation and validation of more than 30 functional specifications of the Enterprise Imaging Platform. With the pilot program complete and software successfully implemented at the initial sites, the Company is now working to roll-out Mach7 Enterprise Imaging Platform in all 25 sites for this radiology group, displacing their legacy vendor neutral archive (VNA) vendor.

The radiology group is one of the oldest and most experienced providers of anesthesiology, neonatology, emergency medicine and radiology services to hospitals and medical facilities across the U.S., generating more than US$185mm revenues per annum. Under the terms of the agreement, Mach7 is unable to disclose the identity of the radiology group until the full production roll-out has been completed and the system is live.

Mach7 will earn a monthly subscription-based fee levied on each study managed by the Enterprise Imaging Platform for at least the next three years. The subscription revenue expected in the first 12 months is approximately A$650,000 (US$500,000). The subscriptionbased revenue model ensures a guaranteed revenue annuity over a period of time and therefore provides an important source of regular cash flow for Mach7.

Mach7 continues to aggressively pursue sales opportunities for its Enterprise Imaging Platform, and is receiving significant interest from potential clients in the U.S. and internationally. The Company is currently participating in “requests for proposals” with multiple health systems across the globe. The proposals offer a mix of subscription-based and license revenue models with a combined contract value of more than A$8m (US$6m).

==> picture [610 x 123] intentionally omitted <==

ASX Announcement

6 May 2016

==> picture [610 x 89] intentionally omitted <==

About Mach7 Technologies:

Mach7 Technologies is a global provider of enterprise image management systems that allow healthcare enterprises to easily identify, connect, and share diagnostic image and patient care intelligence where and when needed. Mach7’s award-winning platform delivers image management including rapid record identification, integration, synchronisation and routing, advanced clinical viewing, and optimized vendor neutral archiving. Mach7 has locations in the U.S., Asia, Australia, Africa and the Middle East. For more information, visit www.mach7t.com

Mach7’s wholly-owned subsidiary, 3D Medical Limited, provides medical specific 3D printing is an exclusive distributor of various synergistic technologies including holographic projection. 3D Medical’s innovative products leverage data already captured by conventional imaging modalities and apply it in more meaningful ways to deliver improved economic and patient outcomes. For more information, visit www.3dmedical.com.au

Mach 7 Technologies Contacts :

Albert Liong

CEO +1 650 743 0167 (U.S.) albert.liong@mach7t.com

Jenni Pilcher

CEO Australia, CFO +61 3 9646 2222 (Australia) jenni.pilcher@mach7t.com

Julia Vaughn Investor Relations (U.S.) +1 802 768 0143 (U.S.) julia.vaughn@mach7t.com

==> picture [610 x 123] intentionally omitted <==